Get started
Author

Crystal L. Mallow

Observed names: Crystal L Mallow, Crystal Mallow, Mallow, Crystal
OpenAlex ID: A5114035061
CXCL13 antibody for the treatment of autoimmune disorders
2015 · Ekaterina Klimatcheva, Tracy Pandina, et al. · BMC Immunology · 125
PDF
SEMA4D compromises blood–brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease
2014 · Ernest S. Smith, Alan Jonason, et al. · Neurobiology of Disease · 121
PDF
Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies
2015 · Elizabeth E. Evans, Alan S. Jonason, et al. · Cancer Immunology Research · 111
Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity
2022 · Elizabeth E. Evans, Vikas Mishra, et al. · Journal of Neuroinflammation · 41
PDF
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
2021 · Michael R. Shafique, Terrence L. Fisher, et al. · Clinical Cancer Research · 32
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
2016 · Casey Ager, Matthew Reilley, et al. · Journal for ImmunoTherapy of Cancer · 17
PDF
Evidence that semaphorin 4D is upregulated in neurons in Huntington’s and Alzheimer’s diseases: Effects of a SEMA4D blocking antibody on FDG‐PET in a clinical trial, and treatment rationale for its use in AD
2020 · Elizabeth E. Evans, Terrence L. Fisher, et al. · Alzheimer s & Dementia · 7
PDF
SEMA4D blocking antibody, pepinemab, is a novel potential treatment for neurodegenerative disease: Clinical proof of concept in Phase 2 HD study supports ongoing clinical development in Phase 1/2 AD study
2023 · Terrence L Fisher, Elizabeth E Evans, et al. · Alzheimer s & Dementia · 4
PDF
Results of SIGNAL‐AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of targeting reactive astrocytes with pepinemab, SEMA4D blocking antibody, in people with mild Alzheimer’s dementia
2024 · Eric R Siemers, Elizabeth E Evans, et al. · Alzheimer s & Dementia · 3
PDF
Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies.
2020 · Michael Rahman Shafique, Terrence Lee Fisher, et al. · Journal of Clinical Oncology · 3
Antibody blockade of semaphorin 4D to sensitize pancreatic cancer to immune checkpoint blockade.
2020 · Luis I. Ruffolo, Nicholas A. Ullman, et al. · Journal of Clinical Oncology · 3
Preliminary results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.
2019 · Michael Rahman Shafique, Terrence Lee Fisher, et al. · Journal of Clinical Oncology · 3
Antibody blockade of semaphorin 4D breaks down barriers to enhance tumoricidal immune infiltration and supports rational immunotherapy combinations
2015 · Elizabeth E Evans, Siwen Hu-Lieskovan, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84).
2022 · Terrence Lee Fisher, Elizabeth E. Evans, et al. · Journal of Clinical Oncology · 2
Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.
2020 · Michael C. Lowe, Brian Olson, et al. · Journal of Clinical Oncology · 2
Abstract CT016: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors
2019 · Gregory B. Lesinski, Terrence L. Fisher, et al. · Cancer Research · 2
Neoadjuvant biomarker trial of pepinemab to enhance nivolumab or ipilimumab activity in resectable head and neck cancer.
2025 · Conor Ernst Steuer, Elizabeth E. Evans, et al. · Journal of Clinical Oncology · 1
PDF
629 Neoadjuvant SEMA4D inhibitor pepinemab combination with nivolumab increases crosstalk between B cell and CD26hi T cell in patients with resectable stage III melanoma
2023 · Ayana T Ruffin, Brian Olson, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
613 Neoadjuvant SEMA4D blockade with nivolumab alters suppressive myeloid cells while elevating B cell and CD26hi T cell infiltration in the tumors of patients with resectable stage III melanoma
2022 · Brian Olson, Crystal Mallow, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.
2020 · Michael Rahman Shafique, Terrence Lee Fisher, et al. · Journal of Clinical Oncology · 1
Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial
2026 · Ayana T. Ruffin, Crystal L. Mallow, et al. · Nature Communications
PDF
Abstract LB-C007: Enhancing immune interactions in tumor with pepinemab SEMA4D blocking antibody
2026 · Elizabeth E. Evans, Crystal Mallow, et al. · Cancer Immunology Research
Targeting SEMA4D/PLXN signaling through reactive glia as a common pathology for the treatment of neurodegenerative disorders
2025 · Elizabeth E Evans, Terrence L Fisher, et al. · Alzheimer s & Dementia
PDF
22 Neoadjuvant pepinemab enhances immune checkpoint blockade in metastatic melanoma characterized by biomarkers of TME reprogramming including tertiary lymphoid structures
2025 · Crystal L Mallow, Ayana T Ruffin, et al. · Regular and Young Investigator Award Abstracts
PDF
Abstract 6007: Neoadjuvant pepinemab enhances DC function associated with mature tertiary lymphoid structures and activity of immune checkpoint blockade in patients with metastatic melanoma
2025 · Elizabeth E. Evans, Crystal Mallow, et al. · Cancer Research
Works count: 80
Citation count: 483
H-index: 7
I10-index: 6
Year
Topic
Type